Sanofi to significantly expand UK inhaler plant
pharmafile | September 15, 2015 | News story | Manufacturing and Production |Â Â Cheshire, Sanofi, manufacturing, productionÂ
Sanofi is gearing up for significant expansion of its inhaler production complex in Cheshire, England.
The French pharma giant has applied for planning permission from local authorities in Cheshire to begin work on a masterplan that will see one building in the complex demolished and another expanded.
The site, on the outskirts of Holmes Chapel village, currently employs 320 staff producing inhalation and nasal spray products to supply markets worldwide. It also supplies materials for clinical trials, including clinical packaging and labels.
Increasing demand for its inhalation products, including contract work, has led Sanofi to prepare to up capacity further by 2017. It is believed the expansion could more than double the number of jobs at the site.
The last expansion at the site came in 2012, when SkyePharma invested £5 million to enable the factory to produce the drug delivery company’s then newly-approved Flutiform asthma inhaler.
A hybrid design and access statement for the new application recorded that Sanofi’s primary objective was to ensure it had sufficient manufacturing and office space and infrastructure to accommodate the increased number of personnel on-site.
Cheshire East Council has set a target decision date of November 26 for Sanofi’s proposals. If it approves the redevelopment, work is expected to begin by late 2015 and be complete by the end of 2016.
Joel Levy
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
